viewAION Therapeutic Inc.

Aion Therapeutic: Meet the team using artificial intelligence to create a full lineup of psychedelic and cannabis therapies

Hear from executives at Aion Therapeutic, Lobe Sciences and Silo Pharma at Proactive's psychedelic-themed virtual showcase event on Tuesday February 23

AION Therapeutic Inc. -

Aion Therapeutic Inc (CSE:AION), Lobe Sciences Ltd (CSE:LOBE) (OTCMKTS: (GTSIF) and Silo Pharma Inc (OTCMKTS:SILO) are presenting at Proactive’s next virtual showcase event on February 23.

The psychedelic-themed event will be hosted by Proactive’s Christine Corrado and kicks off on Tuesday at 1 PM ET.

SIGN-UP: Proactive One2One February 23

Toronto-based Aion Therapeutic Inc (CSE:AION) recently filed five patent applications with the US Patent and Trademark Office related to the combination of medical cannabis with edible and psychedelic mushrooms.

The applications include formulations designed to treat a variety of conditions, including cancer, psychiatric disorders, addiction, viral diseases, obesity and inflammatory disorders.

Aion’s combinatorial treatment formulation discovery platform relies on artificial intelligence (AI) techniques. By utilizing AI, the company plans to create a full line of therapeutic products that includes combinatorial pharmaceuticals, nutraceuticals and cosmeceuticals, as well as individualized treatments for personalized medicine using human genome and other data.

Executive chairman Dr Stephen Barnhill will take participants through the firm’s pharmaceutical research and product development. Aion also operations in Jamaica, where psychedelics are more available.

"Jamaica provides Aion Therapeutic an incredibly unique opportunity in that it is one of the very few countries in the world where mushrooms have never been made illegal and are openly sold,” Barnhill said recently.

“It is worth noting that Aion Therapeutic has this incredible research and development opportunity through our partnership with Apollon Formularies Jamaica Ltd, a CLA-licensed medical cannabis company,” Barnhill added. “This partnership allows Aion Therapeutic to legally discover these unique medical cannabis and medical mushroom combinations for therapeutic product formulations. We believe that we can build a large portfolio of blocking patents while most of the rest of the world faces legal hurdles that limit efforts in this type of research and discovery."

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

Quick facts: AION Therapeutic Inc.


Price: 0.05 CAD

Market Cap: $5.91 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...


Aion Therapeutic Inc presents at Proactive's One2One virtual investor forum

Aion Therapeutic Inc (CSE:AION) CEO,  Dr Stephen Barnhill presents at Proactive's One2One virtual investor forum. The Toronto-based group recently filed five patent applications with the US Patent and Trademark Office related to the combination of medical cannabis with edible and psychedelic...

on 02/23/2021

2 min read